Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:

GlobeNewsWire • Sep 3, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.

GlobeNewsWire • Sep 1, 2026

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.

Seeking Alpha • Aug 28, 2026

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Aug 6, 2026

Arvinas Q2 Earnings Call Highlights

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.

MarketBeat • Aug 4, 2026

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Secured the first-ever regulatory approval of a PROTAC (a type of  heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.

GlobeNewsWire • Aug 4, 2026

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.

Zacks Investment Research • Aug 4, 2026

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.

GlobeNewsWire • Jul 28, 2026